The invention relates to a compound of formula wherein Ar1, Ar2, R1, R2, R3, R4, R5, and R5' or to a pharmaceutically active salt thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).